Literature DB >> 34972699

Thoracic Neuroblastoma: A Novel Surgical Model for the Study of Extra-adrenal Neuroblastoma.

Christa N Grant1, Carson A Wills2, Xiaoming Liu2, Vladimir S Spiegelman2, Hong-Gang Wang2.   

Abstract

BACKGROUND/AIM: Neuroblastoma is clinically and molecularly heterogeneous, with poor outcomes despite multimodal treatment strategies. The primary tumor site is an independent predictor of survival; adrenal tumors have the worst outcomes, while posterior mediastinum tumors carry a more favorable prognosis.
MATERIALS AND METHODS: To elucidate the role of the primary tumor microenvironment in mediating survival outcomes, we developed a mouse model for the study of extra-adrenal neuroblastoma by injecting luciferase-tagged cells into either the subpleural space of the posterior chest or the adrenal gland.
RESULTS: Solid tumors developed in the thoracic cavity at the same rate and efficiency as the adrenal as early as one week post-surgery. The survival rate following surgery was equivalent, though the physiological tolerance for large tumors was lower in the thoracic group.
CONCLUSION: This novel mouse model of survivable extra-adrenal neuroblastoma will enable future investigations of the distinct tumor microenvironments between the adrenal gland and posterior mediastinum.
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Neuroblastoma; adrenal; extra-adrenal; mouse model; orthotopic model; posterior mediastinum; thoracic

Mesh:

Year:  2022        PMID: 34972699      PMCID: PMC8765145          DOI: 10.21873/invivo.12675

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  12 in total

1.  Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

Authors:  Kieuhoa T Vo; Katherine K Matthay; John Neuhaus; Wendy B London; Barbara Hero; Peter F Ambros; Akira Nakagawara; Doug Miniati; Kate Wheeler; Andrew D J Pearson; Susan L Cohn; Steven G DuBois
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

2.  Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts.

Authors:  Tina T Thomas; Sahiti Chukkapalli; Raelene A Van Noord; Melanie Krook; Mark J Hoenerhoff; Jonathan R Dillman; Elizabeth R Lawlor; Valerie P Opipari; Erika A Newman
Journal:  J Vis Exp       Date:  2018-05-25       Impact factor: 1.355

3.  Establishment and characterization of new orthotopic and metastatic neuroblastoma models.

Authors:  Estelle Daudigeos-Dubus; Ludivine LE Dret; Valérie Rouffiac; Olivia Bawa; Ingrid Leguerney; Paule Opolon; Gilles Vassal; Birgit Geoerger
Journal:  In Vivo       Date:  2014 Jul-Aug       Impact factor: 2.155

Review 4.  Neuroblastoma.

Authors:  Nadja C Colon; Dai H Chung
Journal:  Adv Pediatr       Date:  2011

5.  Optimizing orthotopic cell transplantation in the mouse adrenal gland.

Authors:  Cibele C Cardoso; Stefan R Bornstein; Peter J Hornsby
Journal:  Cell Transplant       Date:  2010-06-03       Impact factor: 4.064

6.  Animal models of extracranial pediatric solid tumors.

Authors:  Guido Seitz; Sorin Armeanu-Ebinger; Steven Warmann; Jörg Fuchs
Journal:  Oncol Lett       Date:  2012-08-06       Impact factor: 2.967

7.  Long-term outcomes in patients with stage IV neuroblastoma.

Authors:  Mauricio A Escobar; Jay L Grosfeld; Robert L Powell; Karen W West; L R Scherer; Robert J Fallon; Frederick J Rescorla
Journal:  J Pediatr Surg       Date:  2006-02       Impact factor: 2.545

8.  International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.

Authors:  P F Ambros; I M Ambros; G M Brodeur; M Haber; J Khan; A Nakagawara; G Schleiermacher; F Speleman; R Spitz; W B London; S L Cohn; A D J Pearson; J M Maris
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640

9.  A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.

Authors:  K Althoff; A Beckers; E Bell; M Nortmeyer; T Thor; A Sprüssel; S Lindner; K De Preter; A Florin; L C Heukamp; L Klein-Hitpass; K Astrahantseff; C Kumps; F Speleman; A Eggert; F Westermann; A Schramm; J H Schulte
Journal:  Oncogene       Date:  2014-09-01       Impact factor: 9.867

10.  Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice.

Authors:  Maria Eugenia Marques da Costa; Estelle Daudigeos-Dubus; Anne Gomez-Brouchet; Olivia Bawa; Valerie Rouffiac; Massimo Serra; Katia Scotlandi; Conceição Santos; Birgit Geoerger; Nathalie Gaspar
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

View more
  1 in total

1.  Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.

Authors:  Xiaoming Liu; Carson A Wills; Longgui Chen; Jiawen Zhang; Yuanjun Zhao; Mi Zhou; Jeffrey M Sundstrom; Todd Schell; Vladimir S Spiegelman; Megan M Young; Hong-Gang Wang
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 12.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.